Hypertension, Periodontitis
Conditions
Brief summary
Hypertensive patients with chronic periodontitis will be randomized to either intensive treatment or supragingival hygienic treatment and the effects on blood pressure will be identified.
Interventions
PROCEDUREIntensive Treatment
Intensive Surgical Treatment of Periodontitis
PROCEDUREDental Hygienization Treatment
DRUGChlorhexidine (Intensive Treatment)
Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets
Sponsors
Jagiellonian University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Periodontitis with three or more periodontal pockets with a probing depth (PD) \> 5mm * Bleeding of these periodontal pockets on probing * Have at least 20 natural teeth * Provide informed consent and willingness to cooperate with the study protocol * Age \>25 years old * Absence of other significant oral infections. * Primary Hypertension on stable treatment
Exclusion criteria
* Clinical symptoms of acute inflammatory disorders incl flu, rhinitis, sinusitis etc. within past 3 weeks * Hospitalization for any reason within the past 3 months; Life expectancy of \< 3 years; * Allergic disorders; History of chronic infectious disease, Chronic Obstructive Pulmonary Disease (COPD), tuberculosis; chronic hepatitis B or C infection; interstitial pneumonitis, bronchiectasis; known chronic pericardial effusion, pleural effusion, or ascites; liver disease; * Other known chronic inflammatory or autoimmune condition such as lupus or rheumatoid arthritis, ulcerative colitis or Crohn's disease * Secondary hypertension (known plasma renin screening, abdominal ultrasound with doppler and other investigations) * Non-basal cell malignancy or treated myelo or lymphoproliferative disease within the past 5 years; * Known HIV positive; Immunizations within past 3 months * Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea. * Primary pulmonary hypertension. * Use of systemic or local steroids or immunosuppressive agents within 6 months of the inclusion. * Individual is pregnant or nursing * History of alcohol abuse or unwillingness to limit alcohol consumption to less than 4 drinks per week
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood Pressure Change | 3 months | Ambulatory Blood Pressure Monitoring |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Flow Mediated Dilatation | 3 months | Vascular Function Measurement |
Other
| Measure | Time frame |
|---|---|
| Periodontal Health Score - CAL - Clinical Attachment Loss | 3 months |
| Leukocyte Immunophenotype and Cytokine measurement | 3 months |
| Gingival Index | 3 months |
| The Community Periodontal Index of Treatment Needs Index | 3 months |
| Periodontal Health Score - Probing Depth | 3 months |
Countries
Poland
Contacts
Primary ContactMarta Czesnikiewicz-Guzik, MD PhD
Outcome results
None listed